Genomic and transcriptomic correlates of HER3 expression in prostate cancer. Effect of GLP1-1RA exposure compared to DPP-4i exposure on progression of stage I-III cancer to stage IV cancer.
Real-world outcomes of olaparib with versus without bevacizumab in bevacizumab-naïve BRCA1/2-mutated ovarian cancer. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This abstract ...
Is Progression-Free Survival 2 Ready for Prime Time in US Food and Drug Administration Regulatory Decision Making? The following represents disclosure information provided by authors of this ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in HER2-low/ultralow, hormone receptor–positive (HR+) metastatic breast cancer (mBC) in ...
The impact of dietary patterns on inflammation and colon cancer risk: A retrospective study of 796 patients.
Prevention and Management of Osteoradionecrosis in Patients With Head and Neck Cancer Treated With Radiation Therapy: ISOO-MASCC-ASCO Guideline Clinical Insights This clinical insights article is ...
Total neoadjuvant treatment with long-course radiotherapy versus concurrent chemoradiotherapy in local advanced rectal cancer with high risk factors (TNTCRT): A multicenter, randomized, open-label, ...
Neoadjuvant Immunotherapy for Colorectal Cancer: Too Good to Be True? Despite significant progress and improving outcomes in the management of plasma cell disorders, AL amyloidosis remains ...
Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary ...
1 Patients in the pooled chemo-IO and IO-only arms. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text component.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results